Abstract. Ginsenoside Re is a protopanaxatriol-type saponin isolated from Panax ginseng berry. Although anti-diabetic and anti-hyperlipidemic effects of Re have been reported by several groups, its mechanism of action is largely unknown until now. Here, we examine anti-diabetic and anti-hyperlipidemic activities of Re and action mechanism(s) in human HepG2 hepatocytes and high-fat diet fed C57BL/6J mice. Re suppresses the hepatic glucose production via induction of orphan nuclear receptor small heterodimer partner (SHP), and inhibits lipogenesis via suppression of sterol regulatory element binding protein-1c (SREBP-1c) and its target gene [fatty acid synthase (FAS), stearoyl-CoA desaturase-1 (SCD1)] transcription. These effects were mediated through activation of AMP-activated protein kinase (AMPK), and abolished when HepG2 cells were treated with an AMPK inhibitor, Compound C. C57BL/6J mice were randomly divided into five groups: regular diet fed group (RD), high-fat diet fed group (HFD) and the HFD plus Re (5, 10, 20 mg/kg) groups. Re treatment groups were fed a highfat diet for 6 weeks, and then orally administered Re once a day for 3 weeks. The in vitro results are likely to hold true in an in vivo experiment, as Re markedly lowered blood glucose and triglyceride levels and protected against hepatic steatosis in high-fat diet fed C57BL/6J mice. In conclusion, the current study suggest that ginsenoside Re improves hyperglycemia and hyperlipidemia through activation of AMPK, and confers beneficial effects on type 2 diabetic patients with insulin resistance and dyslipidemia.
Introduction
The metabolic defects of obesity and type 2 diabetes, characterized by insulin resistance, nonalcoholic fatty liver disease and dyslipidemia, lead to an increased risk of cardiovascular disease (1) . It is now becoming evident that the liver has an important role in the control of whole body metabolism of energy nutrients since the liver is the major site for storage and release of carbohydrates and for fatty acid synthesis. Hepatic AMP-activated protein kinase (AMPK) is thought to play a pivotal role in regulating lipid metabolism, glucose homeostasis, and insulin sensitivity (2) . As an energy sensor maintaining cellular glucose homeostasis, AMPK significantly inhibits hepatic glucose output by transcriptional control. The sterol regulatory element-binding protein (SREBP) is a key lipogenic transcription factor that is nutritionally regulated by glucose and insulin (3, 4) . There is an inverse correlation between SREBP and AMPK activities in hepatocytes (5) . AMPK activation by polyphenols can explain their beneficial effects on hepatic lipid accumulation, hyperlipidemia, and atherosclerosis in type 1 diabetic LDL receptor deficient (LDLR -/-) mice (6) . Panax ginseng is a widely used herbal medicine in Asian countries known to have anti-diabetic and anti-hyperlipidemic activities (7) (8) (9) (10) (11) (12) . The principle components for these activities are thought to be the ginsenosides, a group of steroidal saponins. Attele et al (13) reported that Panax ginseng berry extract shows anti-diabetic and anti-obesity effects in C57BL/6J ob/ob mice, and its major constituent is ginsenoside Re. However, it is largely unknown how Re lowers blood glucose and lipid levels. Recently, protopanaxatriol ginsenoside Rg1 (14) and Rg2 (unpublished data) have been reported to suppress the hepatic glucose production through AMPK activation, but protopanaxadiol ginsenosides such as Rb1 and Rg3 have no effects on hepatic glucose production.
Here, we examined whether Re, a main constituent among the protopanaxatriol ginsenosides, suppresses hepatic gluconeogenesis and this effect is associated with the AMPK pathway in human HepG2 hepatocytes. We found that Re suppresses the hepatic glucose production by inhibiting the gene expression Glucose production assay. Cells were cultured on 12-well plates at a density of 3.5x10 5 cells/well. Twenty-four hours after the attachment period, cells were treated with or without Re in a serum-free medium for 3 h. Cells were washed twice with phosphate-buffered saline (PBS) to remove glucose and were incubated for 3 h in glucose production assay medium (glucose-and phenol red-free DMEM containing sodium pyruvate (2 mM) and sodium lactate (20 mM). The medium was collected at the end of the incubation period and analyzed for glucose secreted into the medium using an Amplex Red Glucose/Glucose Oxidase Assay kit (Invitrogen, Carlsbad, CA, USA). Glucose production was normalized to the protein concentration measured by a Bio-Rad protein assay kit (Hercules, CA, USA). All experiments were performed at least three times and representative data are shown.
Animals. Five-week-old C57BL/6J mice were purchased from G-Bio (Gwacheon, Korea). Mice were housed in environmentally controlled conditions with a 12 h light/dark cycle and free access to food and water under constant room temperature (22±2˚C), humidity (50±10%). Mice were randomly divided into five groups: regular diet fed group (RD), high-fat diet fed group (HFD) and HFD plus Re (5, 10, 20 mg/kg) groups. Mice in the RD group were maintained on the standard diet and other mice were fed a high-fat diet for 6 weeks, and then orally administered Re once a day for 3 weeks.
Western blotting. For preparation of whole cell lysates to detect phosphoproteins, cells were washed with ice-cold PBS and , and hybridized with primary antibodies (diluted 1:2,000) overnight at 4˚C. After incubation with horseradish-peroxidase-conjugated secondary antibody (diluted 1:2,000) for 2 h at room temperature, protein bands were detected using an enhanced chemiluminescence Western blotting detection kit (Amersham, Uppsala, Sweden), exposed to X-ray film, and then quantified by a densitometric analysis.
Reverse transcription polymerase chain reaction (RT-PCR).
Total-RNA was isolated using an easy-BLUE total-RNA extraction kit according to the manufacturer's instructions. Single-strand cDNA synthesis was performed as described previously using 5 µg of RNA, oligo(dt)15 primers and reverse transcriptase in a total volume of 50 µl. PCR reactions were performed in a total volume of 20 µl comprising 2 µl of cDNA product, 0.2 mM of each dNTP, 20 pmol of each primer, and 0.8 units of Taq polymerase. PCR was performed at 95˚C for 30 sec, followed by an annealing procedure as indicated in Table I for 30 sec, and 72˚C for 1 min. The last cycle was followed by a final extension step at 72˚C for 10 min. The RT-PCR products were electrophoresed on 1% agarose gels under 100 V and stained with 0.5 µg/ml ethidium bromide. Scanning densitometry was performed using an i-MAX gel image analysis system (Core-Bio, Seoul, Korea).
Biochemical analyses. Blood samples were collected from overnight fasted mice and centrifuged at 3,000 x g for 15 min at 4˚C. Blood glucose, triglyceride and non-esterified fatty acid (NEFA) concentrations were determined using an automatic chemistry analyzer (Erba SmartLab, Mannheim, Germany) and Stanbio reagents (Boerne, TX, USA). Plasma insulin concentrations were determined using a mouse insulin ELISA kit (Central Lab. Animal, Inc., Seoul, Korea).
Liver histological analysis. Livers were fixed in 10% phosphate-buffered formalin acetate at 4˚C overnight and embedded in paraffin wax. Paraffin sections (5 µm) were cut and mounted on glass slides for hematoxylin and eosin (H&E) staining to visualize the lipid droplets.
Statistical analysis. All data are expressed as a mean ± standard error (SE). Comparison between groups was made by ANOVA variance analysis, and significance was analyzed by the Tukey's test. Differences of P<0.05 were considered to be statistically significant.
Results
Re inhibits hepatic glucose production. To examine the cell viability after Re treatment, HepG2 cells were treated with various concentrations of Re (0-80 µM) for 24 h. Re did not show any cellular toxicity up to 80 µM (data not shown). The hepatic glucose production in response to Re and insulin was examined in human HepG2 hepatocytes. Cells were treated with Re and insulin (positive control) as indicated for 3 h. Re inhibited the hepatic glucose production in a concentrationdependent manner (Fig. 1B) . At 20 µM, Re inhibited the hepatic glucose production by 29%, comparable to 100 nM of insulin-treated cells.
Re inhibits hepatic glucose production via the LKB1-AMPK pathway. AMPK is known to be activated by phosphorylation at position 172 of the threonine residue, and the protein levels of the phosphorylated form were determined by immunoblotting with the anti-phospho-Thr172 AMPKα antibody. Re markedly phosphorylated AMPK and ACC (an immediate substrate for AMPK) in a time-and concentration-dependent manner ( Fig. 2A and B) . Next, we examine which upstream kinase regulates AMPK in HepG2 cells. A couple of reports demonstrated that the nearest relative kinases in mammals are the liver kinase B1 (LKB1) and the Ca 2+ /calmodulin-dependent protein kinase kinase β (CaMKKβ) (15, 16) . The AMPK kinase in these cells seems to be LKB1 since Re significantly phosphorylated LKB1 in a time-and concentration-dependent manner ( Fig. 2A and B) , but CaMKKβ was not phosphorylated by Re treatment (data not shown). Finally, to test whether the glucose suppressive effect of Re was dependent on activation of AMPK, a pharmacological approach using a specific inhibitor of AMPK (Compound C) was conducted. HepG2 cells were pretreated with 10 µM of Compound C for 1 h, and then incubated with 20 µM of Re for 3 h. AMPK and ACC phosphorylations and repression of hepatic glucose production caused by Re were all completely reversed in the presence of Compound C (Fig. 2C and D) .
Re inhibits gluconeogenic gene expression via induction of SHP.
A recent study demonstrates that AMPK activation causes up-regulation of SHP gene expression, resulting in suppression of hepatic gluconeogenic gene expression in an animal model (17) . Being an activator of AMPK, effects of Re on the expression of SHP-dependent gluconeogenic genes were examined by RT-PCR. Re up-regulated SHP and down-regulated PEPCK and G6Pase gene expressions in concentration-and time-dependent fashions ( Fig. 3A and B) , and these effects were all reversed in the presence of Compound C (Fig. 3C) . (18) have demonstrated that AMPK directly phosphorylates SREBP-1c and -2. AMPK stimulates Ser 372 phosphorylation, suppresses SREBP-1c cleavage and nuclear translocation, and represses SREBP-1c target gene expression in hepatocytes exposed to high glucose, leading to reduced lipogenesis and lipid accumulation. Here, we examined the effect of Re on the gene expression of SREBP-1c and its target lipogenic enzymes, such as FAS and SCD1, by using RT-PCR. HepG2 cells were treated with 10-40 µM of Re for up to 24 h. Re inhibits gene expression of SREBP-1c, FAS and SCD1 in a concentrationand time-dependent manner ( Fig. 3D and E) . These effects were abolished in the presence of Compound C, indicating that AMPK is necessary for Re to suppress de novo lipogenesis through the down-regulation of lipogenic gene transcription in hepatocytes (Fig. 3F) .
Re inhibits lipogenic gene expression. Li et al

Re stimulates AMPK phosphorylation, suppresses lipogenic and gluconeogenic gene expression, and eliminates excess
fat accumulation in the liver of C57Bl/6J mice. Five-week-old C57BL/6J mice were fed a high-fat diet for 6 weeks, and Re was then administered orally for 3 weeks. After sacrifice, liver tissues were removed, and protein and mRNA were extracted for evaluation of AMPK, ACC, SREBP-1c, FAS, SCD1 and glycerol-3-phosphate acyltransferase (GPAT), respectively. Hepatic phosphorylation of AMPK and ACC was decreased by ~30 and ~20%, respectively, in high-fat diet fed mice and substantially restored by Re treatment (Fig. 4A and B) . To determine the functional consequence of AMPK activation, gene expression of key target proteins was assessed by RT-PCR. Expressions of lipogenic and gluconeogenic genes were also markedly enhanced in the high-fat diet control group, compared to the regular diet fed mice, whereas gene expressions in the liver of Re-treated mice were all significantly reduced in dose-dependent manners (Fig. 4C) . Administration of Re eliminated excess fat accumulation in hepatic intracellular vacuoles, as determined by H&E staining (Fig. 4D) .
Re decreases blood glucose and lipid levels. Blood glucose, insulin, triglyceride and NEFA levels of high-fat diet fed mice were increased by 25.0, 21,5, 38.6 and 35,7%, respectively, when compared to those in regular diet fed mice (Table II) . Blood glucose levels were significantly lowered by 18.9% when the mice were treated with 20 mg/kg dose of Re for a 3 week period. A similar pattern was observed for blood insulin levels. Having decreased glucose and insulin levels, HOMA-IR (insulin resistance index) of the mice treated with 20 mg/kg of Re was significantly decreased by 31.8%, compared to that of the HFD control group. Blood triglyceride levels were also dose-dependently lowered by 4.9, 11.3 and 29.5% when the mice were treated with 5, 10 or 20 mg/kg dose of Re for a 3 week period, respectively. Blood NEFA concentrations were also decreased in a dose-dependent manner, compared to that of the HFD control group.
Discussion
Ginsenoside Re is one of the major bioactive protopanaxatrioltype saponins found in ginseng root and berry. There are some reports demonstrating various pharmacological activities of Re, such as enhancing viability of human CD4(+) T cells through regulation of IFN-γ-dependent autophagy (19) , enhancing an immune response to the influenza vaccine (20) , suppressing electromechanical alternans in cardiomyocytes by opening ryanodine receptors (21) , reducing insulin resistance in adipocytes of high-fat diet rats through inhibition of c-Jun NH 2 -terminal kinase and NF-κB (22) and possessing antioxidant and antihyperlipidemic efficacies in streptozotocin-induced diabetic rats (23) . Since 2000, Yuan and colleagues have focused on the evaluation of the pharmacological activities of ginseng (especially American ginseng) and they have demonstrated the anti-diabetic and anti-obesity activities of ginsenoside Re (13, 24) . However, the anti-diabetic and anti-hyperlipidemic mechanism of Re remains largely unknown. Herein for the first time, we demonstrate the antihyperglycemic and anti-hyperlipidemic effects of Re. We show that activated AMPK is the key mediator through which Re suppresses the glucose production and lipogenesis in the liver.
Using an in vitro experiment, we found that the suppressive effect of Re on hepatic glucose production was dependent on AMPK activation although the molecular mechanism by which Re activates AMPK is not yet known (Fig. 2) . These in vitro results were confirmed in animal experiment using high-fat diet fed C57BL/6J mice. Blood glucose levels of 20 mg/kg Re-administered mice were lowered to the level of regular diet fed mice (Table II) , and AMPK was dose-dependently phosphorylated in Re-treated mice (Fig. 4) . AMPK achieves its downstream effects by direct phosphorylation of immediate substrates as well as long term effects on gene expression. Recently, as a molecular mechanism underlying AMPKmediated PEPCK gene suppression, the phosphorylation of CRTC2, a co-activator of CREB protein, by AMPK was reported. Phosphorylation of CRTC2 at Ser 171 by AMPK confers binding of the protein 14-3-3 and sequestration of CRTC2 out of the nucleus, resulting in inhibition of gluco neogenic gene expression (25) , but Re failed to phosphorylate CTRC2 (data not shown). On the other hand, Lee et al (26) have demonstrated that SHP decreases the CREB-dependent induction of gluconeogenic gene expression and hepatic glucose production via disruption of the CREB•CRTC2 complex due to direct interaction with CREB. When HepG2 cells were treated with Table II . Blood parameters in regular diet fed and high-fat diet fed C57BL/6J mice treated with or without Re. Re, the SHP gene was overexpressed in a time-and concentration-dependent manner and these effects were blunted in the presence of Compound C (an AMPK inhibitor), indicating that Re suppresses the hepatic gluconeogenesis by inducing SHP gene expression via AMPK activation. The delayed response of Re antagonized the stimulatory effects of the CREB•CRTC2 complex-mediated gluconeogenesis through induction of SHP gene expression. SHP directly interacts with CREB, which subsequently inhibits CREB-dependent transcription of the subsequent gluconeogenic gene expression including PEPCK and G6Pase via competition with CRTC2 (Fig. 5) . Activated AMPK is a master regulator of cellular responses to low energy states, coordinating the changes in the activity of enzymes of lipid metabolism and modulating partitioning of fatty acids between the oxidative and biosynthetic pathways. Using in vitro and in vivo experiments, we demonstrate for the first time that Re inactivates lipogenic enzymes by inducing phosphorylation of ACC, as well as by down-regulating transcription factors and enzymes associated with lipid metabolism, such as SREBP-1c, FAS, SCD1 and GPAT via the LKB1-AMPK pathway (Figs. 2-4) . Interestingly, specific deletion of LKB1 kinase in a murine liver model, which results in complete loss of phosphorylated AMPK, leads to a dramatically increased expression of hepatic lipogenic enzymes (27) . Recently, Li et al (18) demonstrated that AMPK interacts with and directly phosphorylates SREBP. Ser 372 phosphorylation of SREBP-1c by AMPK is necessary for inhibition of proteolytic processing and the transcriptional activity of SREBP-1c. Although we did not determine the phosphorylated form of SREBP-1c in the liver, we observed the suppressive effects of Re on the gene expression of SREBP-1c and its target enzymes, which result in improvement of hepatic steatosis. To support the hypothesis that AMPK is an upstream kinase that negatively regulates hepatic SREBP activity, we demonstrated that impaired hepatic AMPK signaling caused by HFD feeding was restored by Re treatment (Fig. 4) .
In summary, we suggest that Re could antagonize the stimulatory effects of the CREB•CRTC2 complex-mediated hepatic gluconeogenesis through induction of SHP expression, suggesting that SHP has an important role in the anti-hyperglycemic effect of Re (Fig. 5) . In addition, Re inhibits de novo biosynthesis of triglyceride in the liver through down-regulation of SREBP-1c and lipogenic enzymes associated with lipid metabolism. Our study provides a novel insight into the molecular mechanisms by which Re affects hepatic gluconeogenesis and steatosis. Further studies are needed to elucidate how Re activates AMPK in the liver and to provide therapeutic strategies to combat insulin resistance, dyslipidemia and hepatic steatosis prevalent in type 2 diabetics.
